Core Insights - Sino Bioking (Tianjin) Biological Pharmaceutical Co., Ltd. is set to launch its recombinant feline interferon product, a Class II new veterinary drug, marking a significant advancement in China's veterinary drug market [1] - The Beijing-Tianjin Zhongguancun Tech Town is emerging as a key hub for biomedical innovation, supporting the national strategy for coordinated development in the Beijing-Tianjin-Hebei region [2][7] Company Developments - Sino Bioking has expanded its R&D and quality control center from 200 to 2,000 square meters and completed a third production line in 2025 [5] - The company has secured over 20 patents and is on a fast track for product development, supported by equity financing from a joint initiative of local financial services [6] Strategic Location and Support - The selection of Beijing-Tianjin Zhongguancun Tech Town as the manufacturing base was influenced by its strategic location and robust support policies [3] - The park's "end-to-end dedicated services" and tailored approval processes have significantly streamlined Sino Bioking's project timeline [4] Future Outlook - The tech town aims to attract more biomedical enterprises and enhance its role in regional industrial upgrading, contributing to China's biopharmaceutical innovation landscape [9] - The local government emphasizes the importance of talent cultivation and optimizing the business environment to foster a thriving ecosystem for biomedical startups [8]